

Sr. No.	Title	Page No.
1.	Introduction	1
1.1	Epidemiology	4
1.2	Pathophysiology	5
1.3	Mycobacterium	6
1.4	Mycobacterial targets	7
1.4.1	Decaprenylphosphoryl- β -D-ribose 2'-epimerase	7
1.4.2	Enoyl acyl carrier protein reductase	7
1.4.3	DNA gyrase	8
1.4.4	ATP synthase	8
1.4.5	Maltosyl transferase	8
1.4.6	Fatty acid synthetase	9
1.4.7	Beta-ketoacyl-ACP synthetase	9
1.4.8	D-Alanine-D-alanine ligase	9
1.4.9	Mycolic acid cyclopropane synthetase	9
1.4.10	Mycobacterial membrane protein large 3	9
1.4.11	Mur enzyme	10
1.4.12	L, D-transpeptidase	10
1.4.13	Alanine racemase	11
1.4.14	Arabinosyl transferase	11
1.4.15	DNA dependent RNA polymerase	11
1.4.16	ATP phosphoribosyltransferase	11
1.4.17	Fatty acid degradation protein D32	12
1.4.18	Mycothiol ligase	12
1.4.19	Methionine aminopeptidase	12
1.4.20	Cytochrome bc1 complex	12
1.4.21	Isocitrate lyase	13
1.4.22	Peptide Deformylase	13
1.5	Treatment regimen	13
1.6	DprE1- the most druggable target	17
1.6.1	Mechanism of action	18
1.6.2	Co crystal structure of DprE	18
1.6.3	Inhibitors	19
1.6.4	Covalent v/s non-covalent	23
1.6.5	Dpre1 inhibitors in clinical trials	23
1.6.6	Development of resistance	24
1.7	References	25

2.	Literature	
2.1	Anti-tubercular agents	36
2.1.1	Chalcones as anti-tubercular agents	36
2.1.2	Five membered heterocycles as anti-TB agents	39
2.1.3	Bicyclic compounds as anti-TB agents	40
2.2	DprE1 inhibitors as Anti-TB agents	45
2.2.1	Benzimidazole based DprE1 inhibitors	46
2.2.2	Hydantoin based DprE1 inhibitors	46
2.2.3	Thiophene based DprE1 inhibitors	46
2.2.4	Quinazoline based DprE1 inhibitors	47
2.2.5	Benzothiazinone based DprE1 inhibitors	47
2.2.6	Imidazole based DprE1 inhibitors	48
2.2.7	Triazole and pyrazolopyridones based DprE1 inhibitors	49
2.2.8	Azaindole based DprE1 inhibitors	49
2.2.9	Pyrrolothiadiazole based DprE1 inhibitors	50
2.2.10	Chalcones based DprE1 inhibitors	50
2.3	References	53
3.	Aim and objectives	59
3.1	Design and development of novel anti-TB agents based on the existing DprE1 inhibitors	59
3.2	Design and development of novel anti-TB agents based on hybrid approach	61
3.3	References	64
4.	Results and discussion	66
4.1	Development of pharmacophore model and 3D-QSAR model using a variety of reported scaffolds as DprE1 inhibitors	67
4.1.1	Selection of dataset	67
4.1.2	Pharmacophore model	67
4.1.3	Analysis of 3D-QSAR model	69
4.1.4	Validation of the pharmacophore model using external dataset	70
4.2	Virtual screening for the identification of new moiety by using various filters like pharmacophore model, molecular modelling and Lipinski rule of five	72
4.2.1	First filter: Pharmacophore model	73
4.2.2	Second filter: Molecular docking	73
4.2.3	Third filter: Lipinski rule of five	73
4.3	Hit optimization through molecular docking techniques	74
4.4	Synthesis of designed compounds	76

4.4.1	Synthesis of 3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (Formula IIIa) based compounds	76
4.4.1.1	Synthesis of 3-amino-4-phenyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (106)	78
4.4.1.2	Synthesis of 5-methyl-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (107)	78
4.4.1.3	Synthesis of 1-bromo-5-methyl-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (108)	79
4.4.1.4	Synthesis of 6-chloro-5-methyl-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (109)	79
4.4.1.5	Synthesis of 5-(chloromethyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (110)	80
4.4.1.6	Synthesis of 5-((substitutedbenzylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (111-116)	80
4.4.1.7	Synthesis of 5-((substitutedphenylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>] pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (117-120)	82
4.4.1.8	Synthesis of 5-((substituted)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (121-125)	84
4.4.2	Synthesis of 3,3-dibenzyl-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione based compounds	86
4.4.2.1	Synthesis of methyl 2-benzyl-2-cyano-3-phenylpropanoate (128)	87
4.4.2.2	Synthesis of 3-amino-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (129)	88
4.4.2.3	Synthesis of 3,3-dibenzyl-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (130)	88
4.4.2.4	Synthesis of 3,3-dibenzyl-1-bromo-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (131)	89
4.4.2.5	Synthesis of 3,3-dibenzyl-6-chloro-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (132)	89
4.4.2.6	Synthesis of 3,3-dibenzyl-5-(chloromethyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (133)	89
4.4.2.7	Synthesis of 5-((substitutedamino)methyl)-3,3-dibenzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (134-141)	90
4.4.3	Synthesis of 3-benzyl-7-hydroxy-5-methylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one based compounds	92
4.4.3.1	Synthesis of methyl-2-cyano-3-phenylpropanoate (142)	93
4.4.3.2	Synthesis of 5-amino-4-benzyl-1,2-dihydropyrazol-3-one (143)	94
4.4.3.3	Synthesis of 3-benzyl-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (144)	94
4.4.3.4	Synthesis of 3-benzyl-6-chloro-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (145)	94

4.4.3.5	Synthesis of 3-benzyl-5-(chloromethyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (146)	95
4.4.3.6	Synthesis of 5-((substituted)methyl)-3-benzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (147-151)	95
4.5	Biological screening of synthesized compounds as anti-TB agents by MABA assay	97
4.5.1	Biological screening of synthesized compounds as anti-TB agents using MABA assay	97
4.5.2	Cell viability assay	98
4.6	Molecular docking, ADMET studies and simulation studies of the synthesized compounds	98
4.6.1	Molecular docking study	99
4.6.2	Pharmacokinetics prediction	101
4.6.3	Molecular simulations	104
4.7	Synthesis of the designed compounds (211-249 and 250-261)	107
4.7.1	Synthesis of 3-(3-oxo-1,3-diphenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one derivatives (211-249)	107
4.7.1.1	Synthesis of substituted chalcones (174-207)	108
4.7.1.2	Synthesis of 3-amino-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (129) and 3-amino-4,4-bis(4-methylbenzyl)-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (210)	109
4.7.1.2.1	Synthesis of methyl-2,2-bis(4-methylbenzyl)-2-cyano-ethanoate (209)	110
4.7.1.2.2	Synthesis of 3-amino-4,4-bis(4-methylbenzyl)-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (210)	110
4.7.1.3	Synthesis of 3-(3-oxo-1,3-diphenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one derivatives (211-249)	110
4.7.2	Synthesis of 3,3-dibenzyl-3,3a-dihydro-5,7-diphenylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one derivatives (250-261)	125
4.8	Biological screening of synthesized compounds as anti-TB agents by MABA assay	129
4.9	Molecular docking, ADMET studies of the synthesized compounds	130
4.9.1	Computational studies of compounds (211-249 and 250-261)	130
4.9.2	ADMET predictions of the compounds (211-249 and 250-261)	133
4.10	References	138
5.	Experimental	140
5.1	Computational studies	140
5.1.1	Hardware and software used in the computational work	140
5.1.1.1	Hardware	140
5.1.1.2	Softwares	140

5.1.2	Selection of dataset	140
5.1.3	Development of pharmacophore model using PHASE	141
5.1.4	Development of 3D-QSAR model	142
5.1.5	Virtual screening	143
5.1.6	Docking of the designed compounds using Autodock	143
5.1.6.1	Ligand preparation	143
5.1.6.2	Protein preparation	143
5.1.6.3	Grid generation	144
5.1.6.4	Protein-ligand interaction	144
5.1.7	ADMET predictions of the designed compounds	144
5.1.8	Molecular simulations	144
5.2	Chemical work	144
	Section I	145
5.2.1	3-Amino-4-phenyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (106)	145
5.2.2	5-Methyl-3-phenylpyrazolo[1,5- <i>a</i>] pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (107)	145
5.2.3	1-Bromo-5-methyl-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (108)	146
5.2.4	6-Chloro-5-methyl-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (109)	147
5.2.5	5-(Chloromethyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (110)	147
5.2.6	5-((Benzylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (111)	148
5.2.7	5-((4-Fuorobenzylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (112)	148
5.2.8	5-((4-Chlorobenzylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (113)	149
5.2.9	5-((4-Methylbenzylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (114)	149
5.2.10	5-((3,4-Dichlorobenzylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (115)	150
5.2.11	5-((4-Methoxybenzylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (116)	151

5.2.12	5-((Phenylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (117)	151
5.2.13	5-((4-Fluorophenylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (118)	152
5.2.14	5-((2-Chlorophenylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (119)	152
5.2.15	5-((4-Methoxyphenylamino)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (120)	153
5.2.16	3-Phenyl-5-((pyridin-4-ylamino)methyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (121)	153
5.2.17	3-Phenyl-5-((pyrrolidin-1-yl)methyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (122)	154
5.2.18	3-Phenyl-5-((piperazin-1-yl)methyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (123)	155
5.2.19	5-(Morpholinomethyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (124)	156
5.2.20	5-((4-Methylpiperazin-1-yl)methyl)-3-phenylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (125)	156
5.2.21	Methyl 2-benzyl-2-cyano-3-phenylpropanoate (128)	157
5.2.22	4,4-Dibenzyl-5-iminopyrazolidin-3-one (129)	157
5.2.23	3,3-Dibenzyl-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (130)	158
5.2.24	3,3-Dibenzyl-1-bromo-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (131)	158
5.2.25	3,3-Dibenzyl-6-chloro-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (132)	159
5.2.26	3,3-Dibenzyl-5-(chloromethyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (133)	159
5.2.27	3,3-Dibenzyl-5-((benzylamino)methyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (134)	160
5.2.28	5-((4-Fluorobenzylamino)methyl)-3,3-dibenzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (135)	160
5.2.29	5-((3-Chlorobenzylamino)methyl)-3,3-dibenzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (136)	161
5.2.30	3,3-Dibenzyl-5-((pyridin-2-ylamino)methyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (137)	161
5.2.31	3,3-Dibenzyl-5-((4-methylbenzylamino)methyl)-pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> , 3 <i>H</i>)-dione (138)	161
5.2.32	5-((2,4-Dichlorobenzylamino)methyl)-3,3-dibenzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (139)	162

5.2.33	5-((4-Methoxybenzylamino)methyl)-3,3-dibenzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (140)	162
5.2.34	3,3-Dibenzyl-5-(morpholinomethyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,3 <i>H</i>)-dione (141)	162
5.2.35	Methyl-2-cyano-3-phenylpropanoate (142)	163
5.2.36	5-Amino-4-benzyl-1,2-dihydropyrazol-3-one (143)	164
5.2.37	3-Benzyl-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (144)	164
5.2.38	3-Benzyl-6-chloro-5-methylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (145)	165
5.2.39	3-Benzyl-5-(chloromethyl)pyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (146)	164
5.2.40	5-((Benzylamino)methyl)-3-benzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (147)	165
5.2.41	5-((4-Fluorobenzylamino)methyl)-3-benzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (148)	165
5.2.42	5-((4-Chlorobenzylamino)methyl)-3-benzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (149)	166
5.2.43	5-((3,4-Dichlorobenzylamino)methyl)-3-benzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (150)	167
5.2.44	5-(Pyridin-4-ylamino)methyl)-3-benzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (151)	167
5.2.45	5-((4-Methylbenzylamino)methyl)-3-benzylpyrazolo[1,5- <i>a</i>]pyrimidine-2,7(1 <i>H</i> ,4 <i>H</i>)-dione (152)	168

Section II

5.2.46	(<i>E</i>)-1,3-Diphenylprop-2-en-1-one (174)	168
5.2.47	(<i>E</i>)-3-(4- Chlorophenyl)-1-phenylprop-2-en-1-one (175)	168
5.2.48	(<i>E</i>)-1-Phenyl-3- <i>p</i> -tolylprop-2-en-1-one (176)	169
5.2.49	(<i>E</i>)-3-(4- Fluorophenyl)-1-phenylprop-2-en-1-one (177)	169
5.2.50	(<i>E</i>)-3-(4- Bromophenyl)-1-phenylprop-2-en-1-one (178)	169
5.2.51	(<i>E</i>)-3-(4- Nitrophenyl)-1-phenylprop-2-en-1-one (179)	169
5.2.52	(<i>E</i>)-3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one (180)	169
5.2.53	(<i>E</i>)-3-(3- Chlorophenyl)-1-phenylprop-2-en-1-one (181)	170
5.2.54	(<i>E</i>)-3-(3- Fluorophenyl)-1-phenylprop-2-en-1-one (182)	170
5.2.55	(<i>E</i>)-3-(3- Bromophenyl)-1-phenylprop-2-en-1-one (183)	170
5.2.56	(<i>E</i>)-3-(3- Nitrophenyl)-1-phenylprop-2-en-1-one (184)	170

5.2.57	(E)-3-(3-Methoxyphenyl)-1-phenylprop-2-en-1-one (185)	171
5.2.58	(E)-3-(2-Nitrophenyl)-1-phenylprop-2-en-1-one (186)	171
5.2.59	(E)-1-(2-Bromophenyl)-3-phenylprop-2-en-1-one (187)	171
5.2.60	(E)-3-(3-Chlorophenyl)-1-(4-chlorophenyl)prop-2-en-1-one (188)	171
5.2.61	(E)-3-(3-Chlorophenyl)-1-p-tolylprop-2-en-1-one (189)	172
5.2.62	(E)-1-(4-Chlorophenyl)-3-(3-nitrophenyl)prop-2-en-1-one (190)	172
5.2.63	(E)-1-(4-Chlorophenyl)-3-(3-methoxyphenyl)prop-2-en-1-one (191)	173
5.2.64	(E)-1-(4-Bromophenyl)-3-phenylprop-2-en-1-one (192)	173
5.2.65	(E)-3-(4-Bromophenyl)-1-p-tolylprop-2-en-1-one (193)	173
5.2.66	(E)-3-(4-Bromophenyl)-1-(4-chlorophenyl)prop-2-en-1-one (194)	173
5.2.67	(E)-1-(4-Chlorophenyl)-3-phenylprop-2-en-1-one (195)	174
5.2.68	(E)-3-(4-Chlorophenyl)-1-p-tolylprop-2-en-1-one (196)	174
5.2.69	(E)-1,3-bis(4-chlorophenyl)prop-2-en-1-one (197)	174
5.2.70	(E)-1-(4-Chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (198)	174
5.2.71	(E)-1-(4-Nitrophenyl)-3-phenylprop-2-en-1-one (199)	175
5.2.72	(E)-1-(4-Chlorophenyl)-3-(4-nitrophenyl)prop-2-en-1-one (200)	175
5.2.73	(E)-1,3-Dip-tolylprop-2-en-1-one (201)	175
5.2.74	(E)-3-Phenyl-1-p-tolylprop-2-en-1-one (202)	175
5.2.75	(E)-3-(4-Fluorophenyl)-1-p-tolylprop-2-en-1-one (203)	176
5.2.76	(E)-3-(4-Chlorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one (204)	176
5.2.77	(E)-1-(3-Chlorophenyl)-3-phenylprop-2-en-1-one (205)	176
5.2.78	(E)-1-(4-Fluorophenyl)-3-p-tolylprop-2-en-1-one (206)	177
5.2.79	(E)-3-(3-Fluorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one (207)	177
5.2.80	Methyl-2,2-bis(4-methylbenzyl)-2-cyano-ethanoate (209)	177
5.2.81	3-Amino-4,4-bis(4-methylbenzyl)-1H-pyrazol-5(4H)-one (210)	178
5.2.82	3-(3-Oxo-1,3-diphenylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (211)	178
5.2.83	3-(1-(4-Chlorophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (212)	179
5.2.84	3-(3-Oxo-3-phenyl-1-p-tolylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (213)	179

5.2.85	3-(1-(4-Fluorophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (214)	180
5.2.86	3-(1-(4-Bromophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (215)	181
5.2.87	3-(1-(4-Nitrophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (216)	181
5.2.88	3-(1-(4-Methoxyphenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (217)	182
5.2.89	3-(1-(3-Chlorophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (218)	182
5.2.90	3-(1-(3-Fluorophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (219)	183
5.2.91	3-(1-(3-Bromophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (220)	183
5.2.92	3-(1-(3-Nitrophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (221)	184
5.2.93	3-(1-(3-Methoxyphenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (222)	184
5.2.94	3-(1-(2-Nitrophenyl)-3-oxo-3-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (223)	185
5.2.95	3-(3-(2-Bromophenyl)-3-oxo-1-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (224)	185
5.2.96	3-(1-(3-Chlorophenyl)-3-(4-chlorophenyl)-3-oxopropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (225)	186
5.2.97	3-(1-(3-Chlorophenyl)-3-oxo-3- <i>p</i> -tolylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (226)	186
5.2.98	3-(3-(4-Chlorophenyl)-1-(3-nitrophenyl)-3-oxopropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (227)	187
5.2.99	3-(3-(4-Chlorophenyl)-1-(3-methoxyphenyl)-3-oxopropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (228)	187
5.2.100	3-(3-(4-Bromophenyl)-3-oxo-1-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (229)	188
5.2.101	3-(1-(4-Bromophenyl)-3-oxo-3- <i>p</i> -tolylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (230)	189
5.2.102	3-(1-(4-Bromophenyl)-3-(4-chlorophenyl)-3-oxopropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (231)	189
5.2.103	3-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (232)	190
5.2.104	3-(1-(4-Chlorophenyl)-3-oxo-3- <i>p</i> -tolylpropylamino)-4,4-dibenzyl-1 <i>H</i> -pyrazol-5(4 <i>H</i>)-one (233)	190

5.2.105	3-(1,3-bis(4-chlorophenyl)-3-oxopropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (234)	191
5.2.106	3-(3-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-oxopropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (235)	192
5.2.107	3-(3-(4-Nitrophenyl)-3-oxo-1-phenylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (236)	192
5.2.108	3-(3-(4-Chlorophenyl)-1-(4-nitrophenyl)-3-oxopropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (237)	192
5.2.109	3-(3-Oxo-1,3-dip-tolylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (238)	193
5.2.110	3-(3-Oxo-1-phenyl-3-p-tolylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (239)	193
5.2.111	3-(1-(4-Fluorophenyl)-3-oxo-3-p-tolylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (240)	194
5.2.112	3-(1-(4-Chlorophenyl)-3-(4-fluorophenyl)-3-oxopropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (241)	194
5.2.113	3-(3-(3-Chlorophenyl)-3-oxo-1-phenylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (242)	195
5.2.114	3-(3-(3-Fluorophenyl)-3-oxo-1-p-tolylpropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (243)	195
5.2.115	3-(1-(3-Fluorophenyl)-3-(4-fluorophenyl)-3-oxopropylamino)-4,4-dibenzyl-1H-pyrazol-5(4H)-one (244)	196
5.2.116	3-(1-Phenyl-3-oxo-3-phenylpropylamino)-4,4-bis(4-methylbenzyl)-1H-pyrazol-5(4H)-one (245)	196
5.2.117	3-(1-(4-Chlorophenyl)-3-oxo-3-phenylpropylamino)-4,4-bis(4-methylbenzyl)-1H-pyrazol-5(4H)-one (246)	197
5.2.118	3-(1-(4-Fluorophenyl)-3-oxo-3-phenylpropylamino)-4,4-bis(4-methylbenzyl)-1H-pyrazol-5(4H)-one (247)	198
5.2.119	3-(1-(4-Tolyl)-3-oxo-3-phenylpropylamino)-4,4-bis(4-methylbenzyl)-1H-pyrazol-5(4H)-one (248)	198
5.2.120	3-(1-(4-Nitrophenyl)-3-oxo-3-phenylpropylamino)-4,4-bis(4-methylbenzyl)-1H-pyrazol-5(4H)-one (249)	199
5.2.121	3,3-Dibenzyl-3,3a-dihydro-5,7-diphenylpyrazolo[1,5-a]pyrimidin-2(1H)-one (250)	199
5.2.122	3,3-Dibenzyl-5-(4-chlorophenyl)-3,3a-dihydro-7-phenylpyrazolo[1,5-a]pyrimidin-2(1H)-one (251)	200
5.2.123	3,3-Dibenzyl-3,3a-dihydro-5-(4-nitrophenyl)-7-phenylpyrazolo[1,5-a]pyrimidin-2(1H)-one (252)	200
5.2.124	3,3-Dibenzyl-3,3a-dihydro-7-phenyl-5-p-tolylpyrazolo[1,5-a]pyrimidin-2(1H)-one (253)	201

5.2.125	3,3-Dibenzyl-5-(4-fluorophenyl)-3,3 <i>a</i> -dihydro-7-phenylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one (254)	201
5.2.126	3,3-Dibenzyl-5-(3-chlorophenyl)-3,3 <i>a</i> -dihydro-7-phenylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one (255)	202
5.2.127	3,3-Dibenzyl-5-(3-fluorophenyl)-3,3 <i>a</i> -dihydro-7-phenylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one (256)	202
5.2.128	3,3-Dibenzyl-7-(4-fluorophenyl)-3,3 <i>a</i> -dihydro-5-phenylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one (257)	203
5.2.129	3,3-Dibenzyl-3,3 <i>a</i> -dihydro-5,7- <i>dip</i> -tolylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one (258)	203
5.2.130	3,3-Dibenzyl-5-(4-fluorophenyl)-3,3 <i>a</i> -dihydro-7- <i>p</i> -tolylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one (259)	204
5.2.131	3,3-Dibenzyl-3,3 <i>a</i> -dihydro-5-phenyl-7- <i>p</i> -tolylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one (260)	204
5.2.132	3,3-Dibenzyl-7-(4-chlorophenyl)-3,3 <i>a</i> -dihydro-5-phenylpyrazolo[1,5- <i>a</i>]pyrimidin-2(1 <i>H</i>)-one (261)	205
5.3	Biological screening	205
5.3.1	MABA	205
5.3.2	Principle	206
5.3.3	Assay Procedure	206
5.3.4	Cell viability assay	207
5.4	References	208
6.	Conclusion	211
	Supplementary material	Si- xxxv